Aequim Alternative Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Aequim Alternative Investments’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-43,000	Closed	-$3.76M	–	102
2024 Q1	$3.76M	Hold	43,000	–	–	0.14%	74
2023 Q4	$4.15M	Hold	43,000	–	–	0.17%	66
2023 Q3	$3.8M	Hold	43,000	–	–	0.14%	71
2023 Q2	$3.73M	Hold	43,000	–	–	0.14%	74
2023 Q1	$4.18M	Buy	43,000 +22,900	+114%	+$2.37M	0.13%	80
2022 Q4	$2.08M	Buy	20,100 +6,100	+44%	+$573K	0.06%	105
2022 Q3	$1.19M	Hold	14,000	–	–	0.03%	115
2022 Q2	$1.16M	Hold	14,000	–	–	0.04%	116
2022 Q1	$1.08M	Hold	14,000	–	–	0.03%	125
2021 Q4	$1.24M	Hold	14,000	–	–	0.04%	101
2021 Q3	$1.08M	Buy	14,000 +2,800	+25%	+$221K	0.04%	91
2021 Q2	$935K	Hold	11,200	–	–	0.04%	93
2021 Q1	$846K	Hold	11,200	–	–	0.05%	81
2020 Q4	$982K	Hold	11,200	–	–	0.07%	71
2020 Q3	$852K	Sell	11,200 -32,800	-75%	-$3.32M	0.11%	63
2020 Q2	$5.43M	Hold	44,000	–	–	0.82%	24
2020 Q1	$3.72M	Buy	44,000 +22,000	+100%	+$1.9M	0.62%	32
2019 Q4	$1.86M	Hold	22,000	–	–	0.35%	43
2019 Q3	$1.48M	Buy	22,000 +11,000	+100%	+$847K	0.3%	40
2019 Q2	$942K	Buy	+11,000	New	+$941K	0.27%	37

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Aequim Alternative Investments's BMRN Position: Q2 2024 in Review

Aequim Alternative Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 43,000 shares — an estimated $3.76M sold.

Aequim Alternative Investments first reported a position in BMRN in Q2 2019 and held it in 20 quarters. The position peaked at $5.43M in Q2 2020. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Aequim Alternative Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Aequim Alternative Investments sold 43,000 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $3.76M.
Aequim Alternative Investments first reported a position in BioMarin Pharmaceuticals in Q2 2019 and held it in 20 quarters.
Aequim Alternative Investments's BioMarin Pharmaceuticals position peaked at $5.43M in Q2 2020.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Aequim Alternative Investments's 13F filing for Q2 2024, filed 12 Aug 2024.